Breast Cancer Research Review, Issue 29

In this issue:

Aerobic training in metastatic breast cancer
Everolimus + fulvestrant in AI-resistant, ER+ metastatic disease
Issues with Oncotype DX® cost-effectiveness analyses
Balance harms and benefits of treatment in elderly
Balixafortide + eribulin in HER2– metastatic disease
Pembrolizumab in ER+/HER2– advanced disease
High lymphocyte counts predict low breast cancer mortality
Assessing platinum-based neoadjuvant chemotherapy in TNBC
Single-agent palbociclib for pretreated ER+/HER2– advanced disease?
Cisplatin + gemcitabine vs paclitaxel + gemcitabine in metastatic TNBC

Please login below to download this issue (PDF)

Subscribe